Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis
Antimicrobial Agents and Chemotherapy · 2023
DOI: 10.1128/aac.00818-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Charles D Giamberardino und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Duke University , Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Meningitis, Cryptococcal, Cryptococcus neoformans, Meningoencephalitis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NIAID NIH HHS, Appili Therapeutics.
Abstract (Originalsprache)
Cryptococcal meningoencephalitis (CM) is a devastating fungal disease with high morbidity and mortality. The current regimen that is standard-of-care involves a combination of three different drugs administered for up to one year. There is a critical need for new therapies due to both toxicity and inadequate fungicidal activity of the currently available antifungal drugs. ATI-2307 is a novel aryl amidine that disrupts the mitochondrial membrane potential and inhibits the respiratory chain complexes of fungi—it thus represents a new mechanism for direct antifungal action. Furthermore, ATI-2307 selectively targets fungal mitochondria via a fungal-specific transporter that is not present in mammalian cells. It has very potent in vitro anticryptococcal activity. In this study, the efficacy of ATI-2307 was tested in a rabbit model of CM. ATI-2307 demonstrated significant fungicidal activity at dosages between 1 and 2 mg/kg/d, and these results were superior to fluconazole and similar to amphotericin B treatment. When ATI-2307 was combined with fluconazole, the antifungal effect was greater than either therapy alone. While ATI-2307 has potent anticryptococcal activity in the subarachnoid space, its ability to reduce yeasts in the brain parenchyma was relatively less over the same study period. This new drug, with its unique mechanism of fungicidal action and ability to positively interact with an azole, has demonstrated sufficient anticryptococcal potential in this experimental setting to be further evaluated in clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases, Duke University , Durham, North Carolina, USA.
- Department of Neurosurgery, Duke University , Durham, North Carolina, USA.
- Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, University of Liverpool , Liverpool, United Kingdom.
- Appili Therapeutics Inc. , Halifax, Nova Scotia, Canada.
ORCID-Profile: Charles D Giamberardino, John R Perfect
Förderung
- Medical Research Council
- NIAID NIH HHS
- Appili Therapeutics
Zitieren
APA
Giamberardino, C. D., Tenor, J. L., Toffaletti, D. L., Palmucci, J. R., Schell, W., Boua, J. V. K., Marius, C., Stott, K. E., Steele, S. L., Hope, W., Cilla, D., & Perfect, J. R. (2023). Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00818-23
Vancouver
Giamberardino CD, Tenor JL, Toffaletti DL, Palmucci JR, Schell W, Boua JVK, et al. Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00818-23
BibTeX
@article{Giamberardino2023,
author = {Giamberardino, Charles D and Tenor, Jennifer L and Toffaletti, Dena L and Palmucci, Julia R and Schell, Wiley and Boua, Jane-Valeriane K and Marius, Choiselle and Stott, Katharine E and Steele, Shelby L and Hope, William and Cilla, Don and Perfect, John R},
title = {Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
doi = {10.1128/aac.00818-23}
}
EUVIMED